ArticleOncology letters2026
Circulating miRNA-30a is associated with favorable therapeutic outcome in patients with gastric cancer treated with neoadjuvant chemotherapy.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy (NAC) represents a cornerstone in the management of locally advanced gastric cancer (GC); however, variability in therapeutic effect underscores the need for additional approaches to support post-operative risk stratification. The present study investigated circulating microRNA (miRNA)-30a as a potential post-treatment, response-associated indicator of therapeutic outcome in patients with GC undergoing NAC. Circulating miRNA-30a expression was measured in serum samples using quantitative real-time polymerase chain reaction (RT-qPCR). NAC-treated patients were stratified into responders (TRG 0-2) and non-responders (TRG 3-5) according to Mandards criteria, while chemotherapy-naive (CT-naive) patients were included as a control group. Circulating miRNA-30a levels were higher in responders compared to non-responders. Elevated miRNA-30a expression was associated with reduced pathological tumor burden, including lower T stage and absence of nodal involvement. ROC analysis demonstrated strong discriminatory performance for distinguishing treatment response. In both univariate and multivariable logistic regression analyses, increased miRNA-30a expression remained independently associated with treatment response. Furthermore, higher miRNA-30a levels were associated with improved overall survival. In conclusion, circulating miRNA-30a is associated with favorable therapeutic outcome in GC and may complement conventional assessment strategies in the post-treatment setting as a response-associated indicator. Further validation in larger, prospective cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.